MedWatch

Novartis eyes double blockbuster potential for Genmab-developed drug

Sclerosis treatment Kesimpta, which was developed by Genmab, could surpass USD 2bn in revenue in the future, says the company selling the drug, Novartis.

Photo: ARND WIEGMANN/REUTERS / X90184

Sclerosis treatment Kesimpta (ofatumumab) will surpass annual sales of USD 2bn over the coming years, said Novartis, the company marketing the drug, on Thursday.

Novartis presented an updated company strategy, which included the top-sales expectation that eight of the company’s marketed medicines have the potential to attain coveted blockbuster status, a title earned when a drug generates USD 1bn within one financial year.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs